FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306404153> ?p ?o ?g. }

• W4306404153 endingPage "5383" @default.
• W4306404153 startingPage "5372" @default.
• W4306404153 abstract "Treatments for advanced small-cell lung cancer (SCLC) patients who are resistant to first-line chemotherapy are limited. Given that antiangiogenic agents and immune-checkpoint inhibitors (ICIs) can confer synergistic therapeutic benefits, combination therapy should be considered. We explored the efficacy and safety of combination therapy with anlotinib and programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors as second-line and subsequent therapy for advanced SCLC.We reviewed advanced SCLC patients at Shanghai Chest Hospital who had received anlotinib in combination with ICIs from November 2016 to November 2020 as second- and subsequent-line treatment. Patients with advanced SCLC who had received paclitaxel monotherapy as second-line treatment were included as the control group.A total of 141 patients were included in the final analysis (40 in the combination therapy group and 101 in the paclitaxel monotherapy group). The median progression-free survival (PFS) times for the combination therapy and paclitaxel monotherapy groups were 3.40 and 2.83 months (p = 0.022), respectively, while the median overall survival (OS) times for the combination therapy and paclitaxel monotherapy groups were 8.20 and 5.87 months (p = 0.048), respectively. Hypertension and hepatic dysfunction were the most pronounced adverse events of combination therapy and two patients changed regimens due to severe fatigue and anorexia.The combination of anlotinib and PD-1/PD-L1 blockade has promising efficacy and safety as a second-line or subsequent therapy for SCLC." @default.
• W4306404153 created "2022-10-17" @default.
• W4306404153 creator A5008206344 @default.
• W4306404153 creator A5009476643 @default.
• W4306404153 creator A5021139793 @default.
• W4306404153 creator A5058563343 @default.
• W4306404153 creator A5067998205 @default.
• W4306404153 creator A5069072350 @default.
• W4306404153 date "2022-10-17" @default.
• W4306404153 modified "2023-10-10" @default.
• W4306404153 title "Efficacy and safety of anlotinib combined with <scp>PD</scp> ‐1/ <scp>PD‐L1</scp> inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer" @default.
• W4306404153 cites W1971264126 @default.
• W4306404153 cites W2073775185 @default.
• W4306404153 cites W2076196097 @default.
• W4306404153 cites W2078530694 @default.
• W4306404153 cites W2101156795 @default.
• W4306404153 cites W2125340209 @default.
• W4306404153 cites W2145708352 @default.
• W4306404153 cites W2170260373 @default.
• W4306404153 cites W2540338380 @default.
• W4306404153 cites W2567690584 @default.
• W4306404153 cites W2753004811 @default.
• W4306404153 cites W2756743534 @default.
• W4306404153 cites W2765782352 @default.
• W4306404153 cites W2783703728 @default.
• W4306404153 cites W2787666307 @default.
• W4306404153 cites W2791328450 @default.
• W4306404153 cites W2791667474 @default.
• W4306404153 cites W2801571624 @default.
• W4306404153 cites W2889570909 @default.
• W4306404153 cites W2890601979 @default.
• W4306404153 cites W2893960509 @default.
• W4306404153 cites W2897191292 @default.
• W4306404153 cites W2898107810 @default.
• W4306404153 cites W2910245285 @default.
• W4306404153 cites W2913745075 @default.
• W4306404153 cites W2923252099 @default.
• W4306404153 cites W2933419869 @default.
• W4306404153 cites W2940341241 @default.
• W4306404153 cites W2947480172 @default.
• W4306404153 cites W2958083922 @default.
• W4306404153 cites W2977392388 @default.
• W4306404153 cites W2995889981 @default.
• W4306404153 cites W3001232216 @default.
• W4306404153 cites W3011919019 @default.
• W4306404153 cites W3021046581 @default.
• W4306404153 cites W3037726457 @default.
• W4306404153 cites W3095089286 @default.
• W4306404153 cites W3098789587 @default.
• W4306404153 cites W3121328438 @default.
• W4306404153 cites W3126928179 @default.
• W4306404153 cites W3127182916 @default.
• W4306404153 cites W3162065781 @default.
• W4306404153 cites W3215130238 @default.
• W4306404153 cites W4306404153 @default.
• W4306404153 doi "https://doi.org/10.1002/cam4.5360" @default.
• W4306404153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36250532" @default.
• W4306404153 hasPublicationYear "2022" @default.
• W4306404153 type Work @default.
• W4306404153 citedByCount "6" @default.
• W4306404153 countsByYear W43064041532022 @default.
• W4306404153 countsByYear W43064041532023 @default.
• W4306404153 crossrefType "journal-article" @default.
• W4306404153 hasAuthorship W4306404153A5008206344 @default.
• W4306404153 hasAuthorship W4306404153A5009476643 @default.
• W4306404153 hasAuthorship W4306404153A5021139793 @default.
• W4306404153 hasAuthorship W4306404153A5058563343 @default.
• W4306404153 hasAuthorship W4306404153A5067998205 @default.
• W4306404153 hasAuthorship W4306404153A5069072350 @default.
• W4306404153 hasBestOaLocation W43064041531 @default.
• W4306404153 hasConcept C121608353 @default.
• W4306404153 hasConcept C126322002 @default.
• W4306404153 hasConcept C143998085 @default.
• W4306404153 hasConcept C197934379 @default.
• W4306404153 hasConcept C2776256026 @default.
• W4306404153 hasConcept C2776694085 @default.
• W4306404153 hasConcept C2776999253 @default.
• W4306404153 hasConcept C2777292972 @default.
• W4306404153 hasConcept C2781230642 @default.
• W4306404153 hasConcept C71924100 @default.
• W4306404153 hasConceptScore W4306404153C121608353 @default.
• W4306404153 hasConceptScore W4306404153C126322002 @default.
• W4306404153 hasConceptScore W4306404153C143998085 @default.
• W4306404153 hasConceptScore W4306404153C197934379 @default.
• W4306404153 hasConceptScore W4306404153C2776256026 @default.
• W4306404153 hasConceptScore W4306404153C2776694085 @default.
• W4306404153 hasConceptScore W4306404153C2776999253 @default.
• W4306404153 hasConceptScore W4306404153C2777292972 @default.
• W4306404153 hasConceptScore W4306404153C2781230642 @default.
• W4306404153 hasConceptScore W4306404153C71924100 @default.
• W4306404153 hasFunder F4320325412 @default.
• W4306404153 hasIssue "5" @default.
• W4306404153 hasLocation W43064041531 @default.
• W4306404153 hasLocation W43064041532 @default.
• W4306404153 hasOpenAccess W4306404153 @default.
• W4306404153 hasPrimaryLocation W43064041531 @default.
• W4306404153 hasRelatedWork W1966838115 @default.
• W4306404153 hasRelatedWork W1968075437 @default.

• next